About Event

Why should you prioritize the 8th IPF Summit in 2024?

In a year marked by notable clinical setbacks, the industry is buoyed by the promise of ongoing phase 2 and phase 3 trials, igniting a sense of hope and excitement throughout the field.  

With new research consistently emerging, technologies being refined and breakthroughs at our fingertips, the ever-present industry challenges remain. With that, lies a unique opportunity to confront these hurdles head-on, drawing invaluable lessons from the clinical failures of the past and leveraging them to fortify and refine our current therapeutic development efforts. 

For the past 8 years, the IPF Summit has consistently provided a vital forum for dedicated pulmonary fibrosis professionals to share knowledge, uncover creative solutions and work together to tackle those ever-present challenges from effective preclinical models to endpoints truly reflective of progress and even innovative clinical trial design, and the 8th IPF Summit returns for 2024 to do exactly that.  

Evvnt Square (49)

150+ Attendees

Evvnt Square (50)

40+ Expert speakers with diverse & insightful presentation

Evvnt Square (51)

8+ Hours of face-to-face networking to build new connections

Evvnt Square (54)

50+ Leading organizations in attendance

Evvnt Square (53)

6 Exclusive interactive pre-conference workshops

Who Will You Meet?

This August, 150+ decision makers representing the leading pulmonary fibrosis biopharma companies will gather together along with the industry’s foremost thought leaders including Toby Maher, Fernando Martinez and Eric White, to name a few.  

This inclusive gathering unites individuals from across the drug development cycle including discovery, preclinical research, translational, biomarker, clinical, regulatory, and patient recruitment, all united in a collective effort to propel innovative and efficacious pulmonary fibrosis therapeutics through Phase 2 and phase 3 to patients in need.

About Page 3
About Page 2
About Page 6